Products Oclacitinib is commercially available in the form of film-coated tablets for dogs (Apoquel). It has been approved in many countries since 2014. Structure and properties Oclacitinib (C15H23N5O2S, Mr = 337.4 g/mol) is present in the drug as oclacitinib maleate. Effects Oclacitinib (ATCvet QD11AH90) has anti-inflammatory, antiallergic, and antipruritic properties. The effects are due to … Oclacitinib
Products Fedratinib was approved in the United States in 2019 in capsule form (Inrebic). Structure and properties Fedratinib is present in the drug as dihydrochloride and monohydrate (fedratinib dihydrochloride monohydrate). Effects Fedratinib has antiproliferative properties. The effects are due to selective inhibition of Janus kinases 2 (JAK2). These are intracellular enzymes that belong to the … Fedratinib
Products Tofacitinib was approved in the United States in November 2012, in many countries in 2013, and in the EU in 2017 in film-coated tablet form (Xeljanz). The European Medicines Agency initially rejected the approval in April 2013. However, baricitinib was approved. In the United States, additional sustained-release film-coated tablets are available that are taken … Tofacitinib
Products Baricitinib was approved in many countries and in the EU in 2017 and in the United States in 2018 in film-coated tablet form (Olumiant). Structure and properties Baricitinib (C16H17N7O2S, Mr = 371.4 g/mol) is structurally related to adenosine triphosphate and interacts with the ATP-binding site of kinases. It is sparingly soluble in water. Effects … Baricitinib
Products Upadacitinib was approved in the US and EU in 2019 and in many countries in 2020 in extended-release tablet form (Rinvoq sustained-release tablets). Structure and properties Upadacitinib (C17H19F3N6O, Mr = 380.4 g/mol) exists in the drug as a hemihydrate. Effects Upadacitinib has selective immunosuppressive and anti-inflammatory properties. The effects are due to selective and … Upadacitinib
Products Ruxolitinib was approved in tablet form in the United States in 2011 and in the EU and Switzerland in 2012 (Jakavi). Structure and properties Ruxolitinib (C17H21N6O4P, Mr = 404.4 g/mol) is present in drugs as ruxolitinib phosphate, a white to light pink powder that is soluble in water. It is a pyrrolopyrimidine pyrazole derivative … Ruxolitinib
